NCT06061471

To Evaluate the Efficacy and Safety of AK111 Injection in the Treatment of Moderate to Severe Plaque Psoriasis

A Randomized, Double-blind, Phase II Clinical Study to Evaluate the Efficacy and Safety of AK111 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 454 (actual)
• Sponsor: Akeso · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized, double-blind phase II clinical study to evaluate the efficacy and safety of AK111 in the treatment of subjects with moderate to severe plaque psoriasis.

Detailed description

This is a randomized, double-blind phase II clinical study to evaluate the efficacy and safety of AK111 in the treatment of subjects with moderate to severe plaque psoriasis. The study has 2 parts: first part (randomized double-blind) and second part (open).

Conditions

• Psoriasis
• Skin Diseases

Interventions

Type	Name	Description
DRUG	AK111	AK111 regimen 1-subcutaneous injection,until week 24.
DRUG	AK111	AK111 regimen 2-subcutaneous injection,until week 24.

Timeline

• Start date: 2023-09-22
• Primary completion: 2024-12-11
• Completion: 2024-12-11
• First posted: 2023-09-29
• Last updated: 2025-01-23

Locations

11 sites across 1 country: China